Scott Schlackman - Mar 8, 2024 Form 4 Insider Report for MEDIFAST INC (MED)

Role: Director
Signature: /s/ Jason L. Groves, attorney-in-fact
Stock symbol: MED
Transactions as of: Mar 8, 2024
Transactions value $: -$123,882
Form type: 4
Date filed: 3/12/2024, 05:18 PM
Previous filing: Nov 9, 2023
Next filing: Jun 24, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MED	Common Stock	Options Exercise	$36K	+1.3K	+12.34%	$27.68	11.8K	Mar 8, 2024	Direct
transaction	MED	Common Stock	Sale	-$51.2K	-1.3K	-10.98%	$39.41	10.5K	Mar 8, 2024	Direct
transaction	MED	Common Stock	Sale	-$109K	-2.75K	-26.13%	$39.46	7.78K	Mar 8, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MED	Stock Option (Right to Buy)	Options Exercise	$0	-1.3K	-100%	$0.00^*	0	Mar 8, 2024	Common Stock	1.3K	$27.68	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is an average price. These shares were acquired in multiple transactions at prices ranging from $39.38 to $39.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote.
F2	The reporting person received 5,000 stock options on February 4, 2016 pursuant to the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan. These options vested in three equal annual installments beginning on February 4, 2017.

Content

The price reported in Column 4 is an average price. These shares were acquired in multiple transactions at prices ranging from $39.38 to $39.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote.

The reporting person received 5,000 stock options on February 4, 2016 pursuant to the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan. These options vested in three equal annual installments beginning on February 4, 2017.